What is the main purpose of this 8-K filing by Regeneron?

The main purpose of this 8-K filing is to formally announce and provide access to Regeneron's financial and operating results for the fourth quarter and the full fiscal year ended December 31, 2015. This is typically done through an accompanying press release.

Where can I find the detailed financial results mentioned in this filing?

The detailed financial and operating results are contained in the press release dated February 9, 2016, which is furnished as Exhibit 99.1 to this 8-K filing. This press release is incorporated by reference.

Does this filing contain forward-looking statements or guidance?

This specific 8-K filing, based on the provided content, primarily reports historical financial and operating results for the period ending December 31, 2015. While the accompanying press release (Exhibit 99.1) may contain forward-looking statements, this filing itself is focused on reporting past performance.

What is the significance of the information not being 'filed' for Section 18 purposes?

The statement that the information 'shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934' means that the company is not assuming liability for the accuracy of this specific information under that particular section of securities law. However, the information is still material and important for investors to consider when evaluating the company's performance.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 9, 2016, to report its financial and operating results for the fourth quarter and full year ended December 31, 2015. The primary purpose of this filing was to provide investors with updated financial performance information and key business developments. The press release, furnished as an exhibit, contains the detailed results and operational highlights that investors should review to understand the company's performance and outlook.

Key Highlights

1Regeneron announced its fourth quarter and full year 2015 financial and operating results via a press release dated February 9, 2016.
2The 8-K filing incorporates by reference the press release detailing these results.
3Investors can find comprehensive financial and operational data for the period ending December 31, 2015, within the furnished press release (Exhibit 99.1).
4The filing serves as a notification mechanism for the release of important quarterly and annual financial performance information.
5The information provided is not deemed 'filed' for Section 18 purposes but is crucial for understanding the company's recent performance.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 9, 2016)

Summary

Key Highlights

Frequently Asked Questions